# A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

> **NCT06739122** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 55 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT06739122
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739122, "A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT06739122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*